Westfield Capital Management
BMRN icon

Westfield Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Westfield Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-654,123
Closed -$50.6M – 248
2021
Q3 		$50.6M Buy
654,123
+35,035
+6% +$2.76M 0.3% 118
2021
Q2 		$51.7M Sell
619,088
-125,697
-17% -$9.96M 0.31% 122
2021
Q1 		$56.2M Sell
744,785
-107,087
-13% -$8.75M 0.35% 108
2020
Q4 		$74.7M Buy
851,872
+214,792
+34% +$17M 0.44% 81
2020
Q3 		$48.5M Sell
637,080
-27,977
-4% -$2.83M 0.31% 104
2020
Q2 		$82M Sell
665,057
-173,600
-21% -$17.3M 0.56% 57
2020
Q1 		$70.9M Buy
838,657
+321,207
+62% +$27.7M 0.62% 50
2019
Q4 		$43.8M Buy
+517,450
New +$39.1M 0.31% 111
2018
Q1 		– Sell
-264,630
Closed -$23.6M – 253
2017
Q4 		$23.6M Buy
264,630
+705
+0.3% +$61.3K 0.18% 177
2017
Q3 		$24.6M Buy
263,925
+152,315
+136% +$13.5M 0.19% 168
2017
Q2 		$10.1M Sell
111,610
-152,395
-58% -$13.9M 0.09% 203
2017
Q1 		$23.2M Buy
264,005
+27,535
+12% +$2.45M 0.2% 153
2016
Q4 		$19.6M Buy
236,470
+34,895
+17% +$3M 0.17% 169
2016
Q3 		$18.6M Buy
+201,575
New +$19M 0.15% 173

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Westfield Capital Management's BMRN Position: Q4 2021 in Review

Westfield Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2021, closing a stake of 654,123 shares — an estimated $50.6M sold.

Westfield Capital Management first reported a position in BMRN in Q3 2016 and held it in 14 quarters. The position peaked at $82M in Q2 2020. 556 funds tracked by Wall St. Rank hold BMRN as of Q4 2021.

  • Westfield Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Westfield Capital Management sold 654,123 BioMarin Pharmaceuticals shares in Q4 2021, an estimated $50.6M.
  • Westfield Capital Management first reported a position in BioMarin Pharmaceuticals in Q3 2016 and held it in 14 quarters.
  • Westfield Capital Management's BioMarin Pharmaceuticals position peaked at $82M in Q2 2020.
  • 556 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2021.

Based on Westfield Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.